Working with DTCGT in the context of research

Andy Singleton Thursday, October 31, 2019





New Results

Parkinson's disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk.

Mike A Nalls, Cornelis Blauwendraat, Costanza L Vallerga, Karl Heilbron, Sara Bandres-Ciga, Diana Chang, Manuela Tan, Demis A Kia, Alastair J Noyce, Angli Xue, Jose Bras, Emily Young, Ranier von Coelln, Javier Simon-Sanchez, Claudia Schulte, Manu Sharma, Lynne Krohn, Lasse Pihlstrom, Ari Siitonen, Hirotaka Iwaki, Hampton Leonard, Faraz Faghri, J Raphael Gibbs, Dena G Hernandez, Sonja W Scholz, Juan A Botia, Maria Martinez, Jean-Chrstophe Corvol, Suzanne Lesage, Joseph Jankovic, Lisa M Shulman, The 23andMe Research Team, System Genomics of Parkinson's Disease (SGPD) Consortium, Margaret Sutherland, Pentti Tienari, Kari Majamaa, Mathias Toft, Alexis Brice, Jian Yang, Ziv Gan-Orr, Thomas M Gasser, Peter M Heutink, Joshua M Shulman, Nicolas A Wood, David A Hinds, John R Hardy, Huw R Morris, Jacob M Gratten, Peter M Visscher, Robert R Graham, Andrew B Singleton, International Parkinson's Disease Genomics Consortium

doi: https://doi.org/10.1101/388165











New Results

Parkinson's disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk.

Mike A Nalls, Cornelis Blauwendraat, Costanza L Vallerga, Karl Heilbron, Sara Bandres-Ciga, Diana Chang, Manuela Tan, Demis A Kia, Alastair J Noyce, Angli Xue, Jose Bras, Emily Young, Ranier von Coelln, Javier Simon-Sanchez, Claudia Schulte, Manu Sharma, Lynne Krohn, Lasse Pihlstrom, Ari Siitonen, Hirotaka Iwaki, Hampton Leonard, Faraz Faghri, J Raphael Gibbs, Dena G Hernandez, Sonja W Scholz, Juan A Botia, Maria Martinez, Jean-Chrstophe Corvol, Suzanne Lesage, Joseph Jankovic, Lisa M Shulman, The 23andMe Research Team, System Genomics of Parkinson's Disease (SGPD) Consortium, Margaret Sutherland, Pentti Tienari, Kari Majamaa, Mathias Toft, Alexis Brice, Jian Yang, Ziv Gan-Orr, Thomas M Gasser, Peter M Heutink, Joshua M Shulman, Nicolas A Wood, David A Hinds, John R Hardy, Huw R Morris, Jacob M Gratten, Peter M Visscher, Robert R Graham, Andrew B Singleton, International Parkinson's Disease Genomics Consortium

doi: https://doi.org/10.1101/388165








2019: Meta 5

Largest meta-analysis of GWAS data to date:


- meta-analysis and conditional analyses
- 37,688 cases (IPDGC+23andMe)
- 18,618 proxy-cases (UKBB)
- 1,417,791 controls (IPDGC+UKBB+23andMe)
- 11,477,547 imputed SNPs (HRC)











29,624 controls 62,037 controls 302,042 controls 935,490 controls





Our experience

- somewhat unusual because of the subject and the companies interest
- expands beyond simple searches for risk loci for disease
 - related conditions (Mendelian randomization)
 - behaviors that influence disease risk
 - disease variability
 - sex based variation
 - bespoke replication






• How good are the data





- How good are the data
 - genetically very good
 - phenotypically not really very different than other clinical studies





- Speed
 - In general as responsive as other research groups.
 - There is a process, but the process works well.
 - Note, our area is perhaps an exception.
 Foundation/philanthropic support has been critical.
- Decisions
 - The company has its own research priorities.
 - Their own target pipeline and/or agreements.
 - Work has to be non-competitive in that regard





- Analysis and QC some barriers to what we can do
 - can look for overlap (checksums)
 - some data types not easily accessible (dosage)
- Sharing
 - the biggest challenge the current policy limits broad data sharing
 - we compartmentalize sharing of results own data sum. stat., available to download, DTCGT results, require separate agreement
- Scale
 - very very good. The capacity to include proxy cases is also substantial





One Future?







YOUR EXPERIENCE FUELING RESEARCH



Share Your Expertise

No one understands Parkinson's better than those living with it every day. By working together, we can help shape the future of research.



Participate Online

Fox Insight easily collects selfreported data about health experiences from those with and without Parkinson's in a number of ways.



Drive Genetic Insights

Eligible individuals can help researchers gain a holistic picture of the disease by participating in a genetic sub-study powered by 23andMe.







Share Data

Join LunaDNA and share your data in a few steps. Your data is de-identified and encrypted to ensure privacy and security.

Help Discovery

Researchers pay to conduct research on the aggregated data.

Earn Benefits

Proceeds earned from research on the platform are passed back to the shareholders who shared their data.



